期刊
ALZHEIMER DISEASE & ASSOCIATED DISORDERS
卷 20, 期 1, 页码 6-15出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.wad.0000191420.61260.a8
关键词
Alzheimer disease; amyloid beta; cerebrospinal fluid; clinical trials; cytokines; isoprostanes; positron emission tomography; tau; volumetric magnetic resonance imaging
资金
- NATIONAL INSTITUTE ON AGING [U19AG010483, R01AG010897] Funding Source: NIH RePORTER
- NIA NIH HHS [R01 AG010897, U19 AG010483] Funding Source: Medline
Biomarkers are likely to be important in the study of Alzheimer disease (AD) for a variety of reasons. A clinical diagnosis of Alzheimer disease is inaccurate even among experienced investigators in about 10% to 15% of cases, and biomarkers might improve the accuracy of diagnosis. Importantly for the development of putative disease-modifying drugs for Alzheimer disease, biomarkers might also serve as indirect measures of disease severity. When used in this way, sample sizes of clinical trials might be reduced, and a change in biomarker could be considered supporting evidence of disease modification. This review summarizes a meeting of the Alzheimer's Association's Research Roundtable, during which existing and emerging biomarkers for AD were evaluated. Imaging biomarkers including volumetric magnetic resonance imaging and positron emission tomography assessing either glucose utilization or ligands binding to amyloid plaque are discussed. Additionally, biochemical biomarkers in blood or cerebrospinal fluid are assessed. Currently appropriate uses of biomarkers in the study of Alzheimer disease, and areas where additional work is needed, are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据